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In this issue of Value in Health, Caro and associates
[1] report on their development of a simulation to
measure the relative costs of two different oral pre-
scription medications for the management of type 2
diabetes mellitus: nateglinide and metformin. The
primary ﬁnding in the study was that patients
treated with nateglinide showed a 3-year treatment
cost reduction of $295 in comparison to metformin,
primarily owing to a 2.4-month reduction in the
time it took patients to achieve dual glycemic con-
trol, as measured by postprandial glucose (PPG)
and hemoglobin A1c determinations (HbA1c). Of
note is the development of a simulation tool that
uses previously reported clinical data to apply the
efﬁcacy of each of the compared agents.
The United States is currently facing a diabetes
epidemic. Although the reasons may be multifacto-
rial, the aging of the population, increasing obesity,
decreased physical activity, and changes in food
consumption appear to be primary drivers [2]. It is
estimated that by the year 2050 we will see a 46%
rise in the number of US citizens with the disease
[3]. Accordingly, any simulation using an easily
understood methodology and readily available lab-
oratory markers to assess or compare the long-term
value of therapies could be an important contribu-
tor to the successful treatment of those who fail
preventive measures and then rely on medical inter-
vention to control the microvascular and macrov-
ascular complications of the disease. As health-care
practitioners, we should not lose site of the simple
fact that much of our current epidemic is indeed
fueled by the increasing weight of younger adults
and children. This, in the true sense of the word, is
a preventable phenomenon given appropriate die-
tary and lifestyle counseling.
So, what should we make of the conclusions of
this particular model? First, we must comment on
the idea of “easily understood” as an important
component for the wide adoption of any new infor-
mation contributing to the care of a diabetic popu-
lation. In this model, the attempt to describe a
simulation of disease burden to estimate shorter-
term results was uniformly met with confusion by
our clinical practitioners. Although the authors
describe their processes, the description falls short
for a clinician-based audience. The study report
could have beneﬁted from a more thorough discus-
sion of the methodologies used given that most clin-
ical practitioners are not familiar with the modeling
methodology employed.
Second, advancing the notion that the use of
HbA1c and PPG in the short term is, as the authors
state, novel did not resonate with our clinicians.
Although it is well recognized that the control of
HbA1c levels in both type 1 and type 2 diabetes is
associated with a decreasing risk of microvascular
complications, the use of PPG as a marker has only
been shown to be of value in patients with gesta-
tional diabetes [4]. Therefore, use of these markers
in the development of a model assessing relative
costs between two therapies is fraught with difﬁ-
culty and requires further research to determine
true contributions.
In addition to this overriding issue, other con-
cerns exist. An expert panel apparently validated
the assumptions related to treatment pathways and
resource use. Nevertheless, standard processes for
reaching consensus with expert panels did not
appear to be incorporated, which would have been
critical to achieve objective, unbiased model
assumptions.
The authors attempted to model real-world treat-
ment patterns by incorporating medication persist-
ency rates. Nevertheless, the assumption of ~80%
persistency at the end of 3 years, although appar-
ently based on one international study, seems opti-
mistic. Additional reference to other studies of
diabetes persistency would be important, as would
a sensitivity analysis of persistency rates. The
authors said that they conducted sensitivity analyses
on all models parameters, but if so, the results were
not shown.
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Similarly, a real-world examination of resource
use patterns, perhaps using medical claims data,
would have provided greater conﬁdence in the treat-
ment assumptions. American Diabetes Association
(ADA) guidelines were used, but the literature is
rich with examples of how routine care patterns dif-
fer from clinical guidelines. Although the authors
recognized this limitation, it is unclear why they did
not collect actual treatment pattern data given its
criticality.
In summary, the study’s likely value for inform-
ing decision-making is limited by the complexity
of the analysis, the lack of consensus as to the im-
portance of the study’s key outcome measure, and
treatment pattern assumptions based on clinical
guidelines rather than routine clinical care. Putting
aside the validity of the dual control as an outcome
measure, the difference of 2.4 months in time to
reach dual glycemic control is an insufﬁcient differ-
ence on which to base a decision. When one con-
siders the limitations of the study and the extent to
which results changed even for the limited sensitiv-
ity analyses that were presented, it becomes entirely
unclear whether a 2.4-month difference would actu-
ally manifest in routine care.
Additional cost-effectiveness research is neces-
sary to assist practitioners with important ques-
tions about which initial therapies to select. Clearly,
diabetes is a progressive disease. Patients who reach
their goal initially on single drug therapy are likely
to require additional therapies later in life to main-
tain acceptable HbA1c levels. At present, the ADA
treatment guidelines [5] give guidance as to what
acceptable treatment goals are. What is not clear is
well-researched guidance as to what initial therapy
may delay progression to the need for additional
add-on therapies, including both oral and injectable
products. We welcome additional research in this
area.
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